- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00822952
Prostate Mechanical Imager (PMI) Clinical Bridging Study (PMI)
Study Overview
Status
Conditions
Detailed Description
The clinical application of a Prostate Mechanical Imaging (PMI) technique for prostate assessment is examined in this study. PMI technology is based on the visualization of internal structures and dimensions of the prostate by measuring mechanical stress patterns on the gland surface with pressure sensor arrays. Temporal and spatial changes in the stress pattern provide information on the hardness of the prostate. Projected patient sample size for the study is 40 men over the age of 21. Patients will be selected for the study if both of the following criteria are met: (1) abnormal DRE findings; and (2) patients who are scheduled for a TRUS-guided prostate biopsy and/ or radical prostatectomy due to an abnormal DRE, and/or increased PSA, and/or other clinical indications.
The study is designed to assess the imaging capability of the PMI in three clinical sites, performed by four physicians. Each clinical investigator will perform PMI examination on 10 respective patients with DRE detected abnormality. Pathology data will be collected from TRUS-guided biopsy or radical prostatectomy and will be used as reference data in case there is a discrepancy between the DRE findings and PMI images. Study Hypothesis: Proportion of patients with PMI reconstructed image is anticipated to be consistent with the 84% imaging capability demonstrated in the previous clinical study conducted with the prior version of the PMI device.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota/VA Medical Center
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- Robert Wood Johnson Medical Center
-
-
New York
-
Garden City, New York, United States, 11530
- AccuMed Research Associates
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17604
- Urology Associates of Lancaster
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- all racial and ethnic groups,
- males 21 years of age or older,
- able to withstand body positioning for the entire length of examination,
- presence of DRE detected abnormality,
- scheduled for TRUS-biopsy or surgical removal or prostate,
- able to comprehend, sign, and date the written informed consent form (ICF)
Exclusion Criteria:
- previous pelvic surgery,
- significant hip and / vertebral arthritis,
- rectal Crohn's disease,
- locally disseminated cancer of pelvic structure,
- anal fissure, anal fistula, infected anal fistula,
- anal cancer,
- rectal cancer,
- 1st, 2nd or 3rd degree hemorrhoids,
- pelvic irradiation,
- dehydrated impacted stool,
- no vulnerable patients such as students, nursing home residents, institutionalized patients, and those with psychological or physical incapacity will be included in the study
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Prostate Mechanical Imager provides reconstructed image of prostate
Time Frame: 1 Year
|
1 Year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Prostate Mechanical Imager recorded images of prostate are consistent with the abnormal digital rectal examination findings
Time Frame: 1 Year
|
1 Year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Armen Sarvazyan, Ph.D., D.Sc., Artann Laboratories
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PMI-03
- 5R44CA082620 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States